There are currently no treatments to prevent or slow the progression of Alzheimer’s disease. Building on Indiana University School of Medicine’s well-established expertise in Alzheimer’s disease research, the Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) drug discovery center aims to address challenges in discovering new therapeutic targets and drugs for the disease and accelerate development of promising new treatments. IU School of Medicine is one of only two institutions in the United States selected by the National Institute on Aging to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.
Learn More
Learn more about TREAT-AD and its mission across both funded U.S. research centers at the TREAT-AD website.
Leveraging partnerships in science and medicine
Video
Discovering new treatments for Alzheimer's disease
There are currently no treatments to prevent or slow the progression of Alzheimer’s disease. TREAT-AD at IU School of Medicine will bring innovative approaches to discovering new therapeutic targets and drugs for the disease and accelerate development of promising new medicines.
Fall 2020
The Search
Matthew Harris | Nov 10, 2020
IU researchers identify new gene mutation that alters Alzheimer’s disease risk
Alzheimer’s disease researchers study gene associated with the brain’s immune cells
IU researchers identify protein that contributes to tau neurotoxicity in Alzheimer’s disease
IU School of Medicine awarded $36 million NIH grant for Alzheimer's disease drug discovery center